SCHEMBL22909283

SCHEMBL22909283

Cc1ccc(-c2c(F)c(F)c(F)c(F)c2S(=O)(=O)N(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.40
PTGS1 P23219 2/20 0.39
AGER Q15109 1/20 0.38
HDAC11 Q96DB2 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
HPGD P15428 1/20 0.36
CA12 O43570 2/20 0.35
CA9 Q16790 2/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
C5AR1 P21730 1/20 0.34
GAA P10253 1/20 0.31
HDAC3 O15379 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29899437 1.00 PTGS2 (0.40) PTGS2PTGS1AGERHDAC11HDAC8
SCHEMBL22909383 0.85 LMNA (0.38) HDAC11HDAC8HDAC6MEN1KMT2A
SCHEMBL22909498 0.83 CA1 (0.40) PTGS2CA12CA9CA1CA2
SCHEMBL29729085 0.83 KIF11 (0.47) PTGS2HDAC6
SCHEMBL29729065 0.83 CA1 (0.40) PTGS2CA12CA9CA1CA2
SCHEMBL22909258 0.83 KIF11 (0.47) PTGS2HDAC6
SCHEMBL22909271 0.73 CA1 (0.43) HDAC11HDAC8HDAC6CA12CA1
SCHEMBL4155727 0.73 ACHE (0.48) PTGS2PTGS1MAPTHPGDCA9
SCHEMBL13170620 0.71 ACHE (0.46) PTGS2PTGS1MAPTHPGDCA9
SCHEMBL4152903 0.71 ACHE (0.46) PTGS2PTGS1MAPTHPGDCA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof 2692372 ONTARIO, INC. (CA) 2026-02-24 US disclosed
US-20220281812-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO INC (CA) 2022-09-08 US disclosed
EP-4017843-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 Ontario, Inc. (CA) 2022-06-29 EP disclosed
WO-2021009568-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2021-01-21 WO disclosed
WO-2021009568-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2021-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof NR2E1, NR2C2, NR3C1 PTGS2 4253/4885PTGS1 3639/4885AGER 1754/4885
US-20220281812-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF BCR, ARSA, VHL PTGS2 3391/4885PTGS1 2996/4885AGER 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.